US 12230364
Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
granted A61PA61P35/00
Quick answer
US patent 12230364 (Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 45
- CPC classes
- A61P, A61P35/00